NKTT 120

Drug Profile

NKTT 120

Alternative Names: NKT-14; NKTT120

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator NKT-Therapeutics
  • Class Anti-inflammatories; Antianaemics; Monoclonal antibodies
  • Mechanism of Action Natural killer cell receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Sickle cell anaemia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Sickle-cell-anaemia in USA (IV)
  • 01 May 2015 NKT Therapeutics completes a phase-I trial in Sickle cell anaemia in USA (IV) (NCT01783691)
  • 08 Dec 2014 Efficacy and adverse event data from a phase Ib trial in Sickel cell anaemia presented at the 56th Annual meeting and exposition of the American Society of Hematology (ASH-Hem-2014)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top